Review · 2016
A Review of Pathophysiology and Management Options for Delayed Ejaculation
Sadowski DJ, Butcher MJ, Köhler TS (2016). A Review of Pathophysiology and Management Options for Delayed Ejaculation. Sexual Medicine Reviews. doi:10.1016/j.sxmr.2015.10.006
This review found no FDA-approved medicine for delayed ejaculation and low-quality evidence for off-label drugs, of which cabergoline and bupropion are the most used; it suggests combining sex therapy with medication or vibratory stimulation.
Summary
The authors reviewed the literature on the causes and treatment of delayed ejaculation (DE), which they describe as a poorly defined disorder involving delay or absence of orgasm that causes personal distress. Because DE has many possible causes, they stress that management should be tailored to the specific cause.
Several psychosexual therapy approaches have been described, but with limited data on how well they work. No medicine is approved by the US Food and Drug Administration for DE, and the quality of evidence for off-label drugs is low; cabergoline and bupropion are the two most commonly used. Penile vibratory stimulation has been described as an add-on option.
The authors conclude that every treatment option has limited supporting evidence and that a multimodal approach, combining psychosexual therapy with medication and/or vibratory stimulation, will likely give the best results.
Limitations
This is a narrative review. The underlying studies are mostly small and uncontrolled, so the authors' recommendation for combined treatment is expert opinion rather than trial evidence.
What it means for you
There is no single proven pill for delayed ejaculation. The most sensible route is to find the cause with a doctor first, then combine approaches, typically sex therapy plus, where appropriate, a medicine change or an off-label option your doctor can explain.